BioXcel soars as FDA gives positive feedback on psychiatric label
BioXcel (BTAI) jumped after saying it received encouraging early FDA feedback ahead of an August 20 meeting on expanding Igalmi's use to at-home psychiatric care. The update follows completion of its pivotal Serenity At-Home Phase 3 trial, with top-line data due this quarter. Analysts see a larger commercial runway, with retail sentiment turning extremely bullish.